| GlaxoSmithKline AG - Boostrix, Injektionssuspension | | 00637 | | 01 | | Boostrix | | Injektionssuspension | | J07AJ52 | | Pertussis, Purified Antigen, Combinations with Toxoids | | 10.08.2000 | | |
| | Composition | | toxoidum diphtheriae ≥ 2 U.I., toxoidum tetani ≥ 20 U.I., toxoidum pertussis 8 µg, haemagglutininum filamentosum 8 µg, pertactinum 2.5 µg, aluminium ut aluminii phosphas et aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, polysorbatum 80, formaldehydum. | | Packungsbestandteile | | Active Agent |
|---|
| Vaccinum Diphtheriae Adsorbatum | | Vaccinum Pertussis Acell. Adsorbatum | | Vaccinum Tetani Adsorbatum |
| | BAG: Active Agent | Dose |
|---|
| Toxoidum Diphtheriae | 2 UI | | Toxoidum Pertussis | 8 mcg | | Toxoidum Tetani | 20 UI |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 003 | | 17.30 | 35.25 | B | SL | No | | 004 | 10 | PR | PR | B | | No |
|
|
